| Followers | 200 |
| Posts | 25597 |
| Boards Moderated | 0 |
| Alias Born | 04/03/2010 |
Saturday, May 03, 2025 10:15:16 AM
I agree. I believe they are working likely to validate with as close to approval as possible. That is usually the most optimal time. A lot of these newer drugs are made by hand in labs for the early trials. Creating a full, automated, commercial facility long before a product is even applied for for approval, is the road to technological death for the most innovative and small bios with the newest ideas and technologies. Of course for Big Pharma, they can do whatever they want. But the FDA killed many early, small bios, decades ago, by forcing them to have full, commercial operations BEFORE their trials even started, at the beginning of this technology. They thought, the end product, in order to be validated, had to be made in the EXACT conditions of a full factory for commercial production, to validate from Phase 1. They killed off many companies and prevented much research. They just did not know any better. They had a hand on the science, but failed to grasp the commercial impossibility they were creating. So it is expected that manufacturing will be part of that process and scale up into the approval and after the approval process, and that's why it happens best at this time, not before, not earlier, because then you have a fallow factory, that you have to maintain in pristine shape and ready to go, when you're not producing any product and there is zero revenue. That is very costly. But the shorts would have you believe that they haven't even started or thought of it yet. The cost for the new clean rooms is lower. The tech is more cost efficient. It has not been some prohibitive, massive investment of billions of dollars to get to this stage and the shorts would of course, speculatively lay it all on thick, make comparisons with other technologies without any thoughtful comparison, and make people fear. Now, that's not to say that market forces will immediately change, or that they won't need to raise funds to scale up if no deal materializes to make it much easier. But the fact is, the shorts know far less than they think they do and they make their money by always predicting the worst, worst case and making it seem as if it is the most likely and most practical reality. That's easy money for them.
Great post TheFollower.
Great post TheFollower.
I own NWBO. My posts on iHub are always posted expressly as just my humble opinion (IMHO) and none are advice, just my opinion. I am NOT a financial advisor, and it is assumed that everyone is responsible for their own due diligence.
Recent NWBO News
- Northwest Biotherapeutics Appoints Dr. Annalisa Jenkins As Strategic Adviser To Advance Dendritic Cell Cancer Vaccine Platform • PR Newswire (US) • 04/30/2026 04:38:00 PM
- Northwest Biotherapeutics Appoints Dr. Annalisa Jenkins As Strategic Adviser To Advance Dendritic Cell Cancer Vaccine Platform • PR Newswire (US) • 04/30/2026 04:30:00 PM
- Northwest Biotherapeutics Announces Establishment Of the Company's Own Dedicated Leukapheresis Clinic • PR Newswire (US) • 04/21/2026 01:30:00 PM
- Northwest Biotherapeutics Announces Establishment Of the Company's Own Dedicated Leukapheresis Clinic • PR Newswire (US) • 04/21/2026 01:30:00 PM
- Form EFFECT - Notice of Effectiveness • Edgar (US Regulatory) • 04/21/2026 04:15:08 AM
- Form POS AM - Post-Effective amendments for registration statement • Edgar (US Regulatory) • 04/16/2026 09:25:30 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 04/07/2026 04:30:50 PM
- Form NT 10-K - Notification of inability to timely file Form 10-K 405, 10-K, 10-KSB 405, 10-KSB, 10-KT, or 10-KT405 • Edgar (US Regulatory) • 03/31/2026 09:04:37 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/15/2026 10:06:20 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/02/2026 10:14:59 PM
- Form DEF 14A - Other definitive proxy statements • Edgar (US Regulatory) • 11/28/2025 09:43:27 PM
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 11/25/2025 10:23:07 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 11/20/2025 09:26:03 PM
- Form PRE 14A - Other preliminary proxy statements • Edgar (US Regulatory) • 11/19/2025 09:15:48 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 11/14/2025 09:44:21 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/31/2025 04:29:10 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/30/2025 08:40:05 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/24/2025 04:28:38 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/14/2025 06:22:26 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 08/14/2025 09:00:38 PM
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 07/01/2025 09:04:38 PM
